Stock comparison
Regeneron Pharmaceuticals
REGN
Market cap
$66.62B
Sector
Healthcare
Overall winner
Regeneron Pharmaceuticals
REGN 4–3 TMO
Thermo Fisher Scientific
TMO
Market cap
$175.7B
Sector
Healthcare
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
REGNvsTMO
64C
52C
68B
74B
48D
40D
26F
28F
45D
51D
59C
52D
57C
45D
Side-by-side metrics
| Metric | REGN | TMO |
|---|---|---|
| Market cap | $66.62B | $175.7B |
| P/E (TTM) | 16.4x | 26.4x |
| EV/EBIT | 20.0x | 27.2x |
| ROIC (TTM) | 8.53% | 7.33% |
| Gross margin | 84.55% | 39.41% |
| Net margin | 29.65% | 15.18% |
| Revenue CAGR 5y | -2.81% | 3.25% |
| EPS CAGR 5y | -13.35% | -2.43% |
| Debt / Equity | 0.1x | 0.8x |
| Dividend yield | 0.51% | 0.36% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
REGN leads on
- Debt / Equity0.1xvs 0.8x+90%
- Gross margin84.55%vs 39.41%+53%
- Net margin29.65%vs 15.18%+49%
- P/E (TTM)16.4xvs 26.4x+38%
TMO leads on
- Revenue CAGR 5y3.25%vs -2.81%+186%
- EPS CAGR 5y-2.43%vs -13.35%+82%
- Market cap$175.7Bvs $66.62B+62%
More like REGN
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.